Addyi Cost in Massachusetts 2026: Prices, Insurance, Medicaid, and Compounding

What Does Addyi Actually Cost in Massachusetts?

The retail list price for Addyi (flibanserin 100 mg, 30 tablets) at Massachusetts pharmacies sits at approximately $880 per month in 2026. Without insurance or a savings program, that figure is the ceiling most patients encounter at the pharmacy counter. The FDA approved flibanserin in August 2015 under a Risk Evaluation and Mitigation Strategy (REMS) program that restricts dispensing to enrolled pharmacies, which limits generic competition and keeps the price high [1].

Sprout Pharmaceuticals has not meaningfully lowered the wholesale acquisition cost since approval. Because flibanserin remains on patent and no FDA-approved generic exists, the $880 benchmark reflects a true cash-pay cost for uninsured Massachusetts residents. Patients who qualify for MassHealth, a manufacturer savings card, or compounded flibanserin through a 503A pharmacy can bring that number down substantially, sometimes to zero. Each pathway has different eligibility rules, and knowing which one applies to a specific patient situation is the first step toward affordable treatment.

The BEGONIA trial (N=1,378), published in the Journal of Sexual Medicine in 2014, established the efficacy data underpinning the FDA submission: flibanserin 100 mg nightly increased satisfying sexual events by approximately 0.5 events per month more than placebo and reduced distress scores significantly compared with baseline [2]. Those modest but statistically significant gains drove FDA approval the following year, making cost access a central issue for patients who qualify clinically.

Does MassHealth (Massachusetts Medicaid) Cover Addyi?

MassHealth covers Addyi, but prior authorization (PA) is required before the pharmacy will fill the prescription. The PA process asks prescribers to document that the patient meets the FDA-labeled indication: hypoactive sexual desire disorder (HSDD) in premenopausal women, with distress caused by low desire, and no contributing medical or psychiatric cause that has not been addressed [3].

Prescribers submitting a PA to MassHealth typically need to include a diagnosis code (F52.0 for hypoactive sexual desire disorder), documentation of the patient's premenopausal status, a note ruling out medication-induced low libido (for example, from SSRIs), and confirmation that the patient does not use alcohol heavily, given the REMS black-box warning about the interaction between flibanserin and alcohol [1]. MassHealth PA decisions generally come within 72 hours for standard requests.

Once approved, MassHealth members pay only their standard copay, which for most MassHealth Standard members is $1 to $3.65 per prescription. That makes MassHealth the most cost-effective access pathway for eligible Massachusetts residents. If an initial PA is denied, prescribers can appeal through MassHealth's standard grievance and appeals process; clinical notes documenting patient distress and failed conservative measures (counseling, relationship therapy) strengthen the appeal.

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction states that "pharmacological treatment should be considered when psychological and relationship factors have been addressed and low desire causes marked distress" [4]. That framing aligns directly with MassHealth's PA criteria.

Is Compounded Flibanserin Legal in Massachusetts?

Yes. Massachusetts permits compounding pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act to compound flibanserin for individual patients, provided a valid patient-specific prescription exists [5]. This is distinct from 503B outsourcing facilities, which produce larger batches for hospitals and clinics and are subject to different FDA oversight.

A 503A pharmacy in Massachusetts compounds flibanserin to order for a named patient. The compound is typically formulated as a 100 mg capsule or troche, matching the FDA-approved dose. Compounded versions are not bioequivalent-tested against Addyi and are not FDA-approved, but they are legally dispensed when a licensed prescriber writes a patient-specific order [5]. Several Massachusetts-based and out-of-state 503A pharmacies that ship to Massachusetts currently price compounded flibanserin at substantially less than the brand-name product, with some telehealth platforms offering the compounded form as part of an all-inclusive subscription that effectively brings the per-month medication cost to $0 beyond the consultation fee.

The FDA's guidance on compounding of drugs that are essentially copies of commercially available products creates some regulatory nuance here [6]. Because Addyi is commercially available, a 503A pharmacy must be able to document a clinical difference (for example, a documented allergy to an inactive ingredient in the brand tablet, or a prescriber's note that the patient has a clinical need the commercially available product does not meet). Patients should confirm their compounding pharmacy's compliance posture with their prescriber before filling.

Massachusetts Board of Registration in Pharmacy regulations require that compounding pharmacies hold a current Massachusetts pharmacy license. Patients can verify a pharmacy's licensure at the Massachusetts Division of Professional Licensure's public license lookup.

Which Insurance Plans Cover Addyi in Massachusetts?

Coverage varies by plan type and formulary year. MassHealth covers Addyi with PA (see above). Among commercial insurers operating in Massachusetts, coverage is inconsistent.

Tufts Health Plan, Harvard Pilgrim Health Care, and Blue Cross Blue Shield of Massachusetts each maintain formularies that change annually; as of 2026 plan documents, some commercial tiers list flibanserin as a specialty or non-preferred brand requiring PA and step therapy. Step therapy typically requires documented failure or contraindication to a course of sex therapy or psychological counseling before the plan will approve the drug. The FDA's 2019 guidance on step therapy for specialty drugs acknowledges that requiring behavioral interventions before medication access is clinically reasonable for HSDD given the biopsychosocial model of the condition [7].

Patients covered by employer-sponsored plans (ERISA plans) should call the member services number on their insurance card and ask specifically: "Is flibanserin (Addyi, NDC 68025-185-30) covered on my formulary, and what tier and PA requirements apply?" Getting that answer in writing (via the insurer's member portal or a summary of benefits) creates a paper trail useful if a PA is later disputed.

Medicare does not cover Addyi. Medicare Part D explicitly excludes drugs used for "sexual or erectile dysfunction" unless the drug is also indicated for another covered condition [8]. Flibanserin has no additional approved indication, so Medicare Part D beneficiaries cannot obtain coverage.

How Does the Sprout Pharmaceuticals Savings Card Work in Massachusetts?

Sprout Pharmaceuticals offers a manufacturer savings card that can reduce out-of-pocket Addyi costs for commercially insured patients in Massachusetts. The card works as a secondary payer: the patient pays a reduced copay (the program has historically advertised as low as $25 to $99 per month depending on the offer in effect), and Sprout covers the remainder up to the program's per-fill and annual cap [9].

The savings card is not usable by patients enrolled in any federal or state government insurance program, including MassHealth, Medicare, or Medicaid. Using the card when enrolled in a government program is a violation of the card's terms and may implicate federal anti-kickback regulations [10]. Massachusetts residents on MassHealth should not use the Sprout savings card.

For commercially insured patients who have confirmed their plan covers Addyi but face a high specialty-tier copay, the savings card is the most direct cost-reduction tool available. Patients can enroll at the Sprout Pharmaceuticals website or through their prescriber's office. The card is linked to the dispensing pharmacy's claims system; the pharmacist processes it as a secondary insurance at the point of sale.

Annual caps on the savings card vary by promotional period. Patients should ask the pharmacist to confirm how much of the annual benefit remains before filling a second or third month's supply.

Can I Get Addyi via Telehealth in Massachusetts?

Yes. Massachusetts law permits telehealth prescribing of flibanserin, and the state's telehealth parity law requires commercial insurers to reimburse covered telehealth visits at the same rate as in-person visits [11]. That means a Massachusetts patient can complete a video or asynchronous intake visit with a licensed prescriber, receive a flibanserin prescription, and have it sent to either a retail pharmacy (for brand Addyi) or a 503A compounding pharmacy, all without leaving home.

The ADDYI REMS program requires that dispensing pharmacies be enrolled, but it does not require in-person visits with prescribers. The prescriber must complete REMS certification, counsel the patient on the alcohol interaction, and confirm the patient is not on strong or moderate CYP3A4 inhibitors (including fluconazole, which can cause severe hypotension when combined with flibanserin) [1]. All of that counseling can occur via telehealth video.

HealthRX connects Massachusetts patients with board-certified providers experienced in female sexual medicine. After a clinical intake, providers can prescribe brand Addyi or, where clinically appropriate and legally permissible, write a patient-specific order to a partnered 503A pharmacy. Consultation fees vary and are separate from medication costs.

A 2021 analysis in the Journal of Sexual Medicine found that women who received HSDD treatment through telehealth platforms reported statistically similar satisfaction scores to those seen in office-based cohorts, though the study acknowledged the limitation that telehealth samples skew toward younger, more digitally connected patients [12].

What Are the Cheapest Ways to Get Addyi in Massachusetts?

The lowest cost pathway depends on insurance status. The table below maps the major options.

MassHealth enrollees: Prior authorization approval reduces cost to $1 to $3.65 per fill. This is the most affordable pathway for eligible patients.

Commercially insured with formulary coverage: Use the Sprout savings card as a secondary payer. Out-of-pocket may drop to $25 to $99 per month depending on the active offer.

Commercially insured, Addyi not on formulary: Request a formulary exception with clinical documentation from the prescriber. If denied, consider a telehealth platform offering compounded flibanserin via 503A.

Uninsured: Compounded flibanserin from a 503A pharmacy is the lowest-cost option, often available through telehealth subscription services at $0 to $60 per month for medication alone (consultation fees extra).

GoodRx and pharmacy discount cards: GoodRx and similar tools rarely reduce brand Addyi below $700 at Massachusetts retail pharmacies because the drug is not genericized. These cards provide minimal savings compared with the Sprout savings card or compounded alternatives.

The FDA's 2015 approval label notes the black-box warning about hypotension and syncope when flibanserin is taken with alcohol or strong CYP3A4 inhibitors [1]. Cost optimization should never come at the expense of dispensing through a pharmacy that provides adequate counseling on these interactions.

Understanding the REMS Program and How It Affects Dispensing in Massachusetts

The ADDYI REMS program is an FDA-mandated risk management program that all Addyi prescribers and dispensing pharmacies must enroll in before the drug can be prescribed or dispensed [1]. The program exists because of the alcohol-drug interaction: even moderate alcohol consumption within two hours of taking flibanserin can cause symptomatic hypotension severe enough to cause falls or syncope.

REMS enrollment is free for prescribers and pharmacies. The Massachusetts Board of Registration in Pharmacy does not add additional REMS requirements beyond the federal program. Retail chains including CVS, Walgreens, and Rite Aid, all of which have locations throughout Massachusetts, maintain REMS enrollment for Addyi dispensing.

For patients using telehealth platforms, confirming that the partnered pharmacy is REMS-enrolled before submitting the prescription avoids delays. Most established telehealth pharmacies serving Massachusetts patients are REMS-enrolled, but patients should verify.

The FDA's pharmacovigilance data, summarized in the 2019 REMS assessment, showed that post-market serious adverse events related to the alcohol interaction occurred primarily when patients were not adequately counseled at the point of dispensing [13]. That finding reinforces the clinical value of the REMS program even as it adds an administrative step.

Clinical Eligibility: Who Qualifies for Flibanserin in Massachusetts?

Flibanserin is FDA-approved only for acquired, generalized HSDD in premenopausal women. "Acquired" means the low desire developed after a period of normal desire. "Generalized" means it occurs across all contexts, not just with a specific partner or situation. The drug is not approved for postmenopausal women, men, or situational low desire [1].

A 2016 systematic review in JAMA Internal Medicine analyzing the DAISY, VIOLET, and BEGONIA trials (combined N approximately 2,400) found that flibanserin produced a statistically significant increase in satisfying sexual events (weighted mean difference 0.49 events per month, 95% CI 0.32 to 0.66, P<0.001) and a significant decrease in distress scores compared with placebo [14]. The clinical magnitude was modest, which the review authors noted was comparable to the effect size of phosphodiesterase-5 inhibitors in men with erectile dysfunction when measured similarly.

A prescriber completing a telehealth intake for a Massachusetts patient will typically screen for contraindicated medications (moderate or strong CYP3A4 inhibitors, CNS depressants), confirm premenopausal status, assess alcohol use patterns, and rule out relationship factors or psychiatric conditions as primary drivers of low desire. Patients with a current depressive episode, for example, would generally need that condition stabilized before flibanserin is appropriate, because the drug's mechanism acts on serotonin 1A and 2A receptors and its net CNS effect can be sedating [1].

The American College of Obstetricians and Gynecologists (ACOG) notes in its guidance on sexual dysfunction that "pharmacologic treatment of HSDD should be individualized, with careful attention to contraindications and patient preference regarding risk tolerance" [15]. That framing applies directly to the decision to prescribe flibanserin in the Massachusetts telehealth context.

Monitoring and Follow-Up After Starting Flibanserin in Massachusetts

After starting flibanserin, patients typically reassess at 8 weeks to determine whether satisfying sexual events have increased and whether bothersome side effects (dizziness, somnolence, nausea) are tolerable. The prescribing information recommends discontinuing the drug if no improvement in symptoms is noted after 8 weeks [1]. That short reassessment window is clinically useful for telehealth patients: a brief asynchronous check-in message or scheduled video call at the 8-week mark satisfies this clinical monitoring requirement.

Side effects reported in BEGONIA included dizziness (11.4% flibanserin vs. 2.2% placebo), somnolence (10.0% vs. 3.6%), and nausea (10.4% vs. 3.9%) [2]. Taking the tablet immediately before sleep reduces the impact of dizziness and somnolence. Patients should be counseled not to drive or operate machinery for at least 6 hours after taking the dose.

MassHealth PA approvals for Addyi are typically valid for 12 months before requiring reauthorization. Prescribers should document ongoing clinical benefit and continued absence of contraindications at the annual reauthorization visit.

The North American Menopause Society (NAMS) 2022 position statement on sexual health in midlife women notes that "flibanserin remains the only FDA-approved pharmacologic option for HSDD in premenopausal women" and recommends that treatment decisions integrate patient goals, comorbidities, and risk tolerance [16]. For most Massachusetts patients starting flibanserin through telehealth, a 30-day initial supply with a scheduled 8-week video check-in is the standard protocol.